BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained…
<!-- Name:DistributionId Value:8755977 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
BioCryst Pharmaceuticals
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of…
<!-- Name:DistributionId Value:8742059 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the…
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted…
BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway…
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, demonstrated…
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved…
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE…
RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 and…
European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor,…
RESEARCH TRIANGLE PARK, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to…
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials…
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930…
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the RENEW…
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as…
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal…